鲍曼不动杆菌中 PER 型和 NDM 型β-内酰胺酶对头孢地尔罗耐药性的贡献。
Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.
机构信息
Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourggrid.8534.a, Fribourg, Switzerland.
INSERM European Unit (IAME), University of Fribourggrid.8534.a, Fribourg, Switzerland.
出版信息
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0087721. doi: 10.1128/AAC.00877-21. Epub 2021 Jul 12.
Abstract
Cefiderocol (FDC) is a recently developed siderophore cephalosporin showing excellent antibacterial activity against Gram-negative bacteria, including Acinetobacter baumannii. By investigating a series of A. baumannii clinical isolates with elevated MICs of FDC, we showed that PER-like β-lactamases and, to a lesser extent, NDM-like β-lactamases, significantly contributed to reduced susceptibility to that antibiotic. Interestingly, we showed that combination of FDC with avibactam exhibited excellent activity against all multidrug-resistant isolates coproducing OXA-23 and PER-type β-lactamases.
摘要
头孢地尔（FDC）是一种新开发的铁载体头孢菌素，对革兰氏阴性菌（包括鲍曼不动杆菌）具有优异的抗菌活性。通过研究一系列 FDC 药敏MIC 升高的鲍曼不动杆菌临床分离株，我们发现 PER 样β-内酰胺酶，以及在较小程度上，NDM 样β-内酰胺酶，显著降低了对该抗生素的敏感性。有趣的是，我们发现 FDC 与阿维巴坦联合使用对所有同时产 OXA-23 和 PER 型β-内酰胺酶的多药耐药株均具有出色的活性。
相似文献
1
Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0087721. doi: 10.1128/AAC.00877-21. Epub 2021 Jul 12.
2
Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01221-20.
3
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.
4
Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria.
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.01582-20.
5
Acinetobacter baumannii and Cefiderocol, between Cidality and Adaptability.
Microbiol Spectr. 2022 Oct 26;10(5):e0234722. doi: 10.1128/spectrum.02347-22. Epub 2022 Sep 29.
6
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
7
Structural Basis of PER-1-Mediated Cefiderocol Resistance and Synergistic Inhibition of PER-1 by Cefiderocol in Combination with Avibactam or Durlobactam in Acinetobacter baumannii.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0082822. doi: 10.1128/aac.00828-22. Epub 2022 Nov 15.
8
Efficacy of Cefiderocol, a Novel Siderophore Cephalosporin, against Multidrug Resistant Acinetobacter baumannii Clinical Isolates in Japan.
Jpn J Infect Dis. 2024 May 23;77(3):178-181. doi: 10.7883/yoken.JJID.2023.364. Epub 2024 Jan 31.
9
Contribution of Iron-Transport Systems and β-Lactamases to Cefiderocol Resistance in Clinical Isolates of Acinetobacter baumannii Endemic to New York City.
Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0023423. doi: 10.1128/aac.00234-23. Epub 2023 May 22.
10
Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii.
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0264620. doi: 10.1128/AAC.02646-20.
引用本文的文献
1
Evaluating Antimicrobial Susceptibility Testing Methods for Cefiderocol: A Review and Expert Opinion on Current Practices and Future Directions.
Antibiotics (Basel). 2025 Jul 28;14(8):760. doi: 10.3390/antibiotics14080760.
2
Phenotypic and genotypic analysis of isolated from combat wounds in Ukraine during 2022 and 2023.
JAC Antimicrob Resist. 2025 Aug 7;7(4):dlaf140. doi: 10.1093/jacamr/dlaf140. eCollection 2025 Aug.
3
Carbapenem Resistance in : Mechanisms, Therapeutics, and Innovations.
Microorganisms. 2025 Jun 27;13(7):1501. doi: 10.3390/microorganisms13071501.
4
treatment strategies: a review of therapeutic challenges and considerations.
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0106324. doi: 10.1128/aac.01063-24. Epub 2025 Jul 9.
5
Combined resistance mechanisms leading to high-level of cefiderocol resistance among NDM-like producing E. coli ST167 clinical isolates.
Eur J Clin Microbiol Infect Dis. 2025 May 27. doi: 10.1007/s10096-025-05166-w.
6
Evolution of an extensively antibiotic resistant sublineage of lineage 1 of GC1 Acinetobacter baumannii.
NPJ Antimicrob Resist. 2025 May 9;3(1):36. doi: 10.1038/s44259-025-00103-5.
7
The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-Resistant .
Microorganisms. 2025 Apr 5;13(4):829. doi: 10.3390/microorganisms13040829.
8
Outbreak of High-Risk Clone ST323 Resistant to Ceftazidime-Avibactam Due to Acquisition of and to Cefiderocol Due to Mutated Gene.
Antibiotics (Basel). 2025 Feb 21;14(3):223. doi: 10.3390/antibiotics14030223.
9
Iron-dependent mechanisms in : pathogenicity and resistance.
JAC Antimicrob Resist. 2025 Mar 19;7(2):dlaf039. doi: 10.1093/jacamr/dlaf039. eCollection 2025 Apr.
10
Epidemiological and genomic analysis of strains from retailed raw meat.
Heliyon. 2024 Dec 25;11(1):e41487. doi: 10.1016/j.heliyon.2024.e41487. eCollection 2025 Jan 15.
本文引用的文献
1
Comparison of Agar Dilution to Broth Microdilution for Testing Activity of Cefiderocol against Gram-Negative Bacilli.
J Clin Microbiol. 2020 Dec 17;59(1). doi: 10.1128/JCM.00966-20.
2
Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria.
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.01582-20.
3
Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3.
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01221-20.
4
Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
Antimicrob Agents Chemother. 2020 Sep 21;64(10). doi: 10.1128/AAC.00797-20.
5
Activity of Cefiderocol Against , , and Endemic to Medical Centers in New York City.
Microb Drug Resist. 2020 Jul;26(7):722-726. doi: 10.1089/mdr.2019.0298. Epub 2020 Feb 7.
6
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S544-S551. doi: 10.1093/cid/ciz827.
7
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S538-S543. doi: 10.1093/cid/ciz826.
8
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S565-S575. doi: 10.1093/cid/ciz830.
9
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.
J Antimicrob Chemother. 2019 Jul 1;74(7):1934-1939. doi: 10.1093/jac/dkz149.
10
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
Zotero 插件